 |
|
|
|
|
|
|
|
 |
Results for 'Pipeline Insight: Alzheimer's Disease' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Pipeline and Commercial Insight: Alzheimer's Disease
Scenario Forecasts Reveal Vast Market Potential
|
March 2008 |
£7600 |
100 % |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
63 % |
Pipeline Insight: Disease Modification In Rheumatoid Arthritis
Pipeline Uptake Inhibited By Anti-TNFs
|
October 2005 |
£6495 |
63 % |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
63 % |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
63 % |
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome
Reformulations set to drive near-term growth
|
August 2006 |
£8695 |
62 % |
Central Nervous System - Alzheimer Disease Drug Pipeline Report
|
February 2008 |
£1495 |
50 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1510 |
43 % |
Molecular Insight Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
35.5 % |
Stakeholder Insight: Alzheimer's Disease
Prescribing trends indicate that neurologists are not adhering to guidelines
|
December 2006 |
£8000 |
35 % |
KV Pharmaceutical Co. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Keryx Biopharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Jazz Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Isis Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Introgen Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Inyx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Iomai Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
IsoRay Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Javelin Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
LAM Pharmaceutical Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lev Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lescarden Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lexicon Pharmaceuticals, Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Ligand Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lorus Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lee Pharmaceuticals -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lannett Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Kosan Biosciences Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Kyto BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
La Jolla Pharmaceutical Co -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Labopharm Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
King Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Intellect Neurosciences, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Immunomedics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
ImmunoGen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Impax Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
InNexus Biotechnology Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
InSite Vision Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Immtech Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Imclone Systems Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Idenix Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Idera Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Imagenetix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Imarx Therapeutics, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Incyte Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Indevus Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Inspire Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
IntelGenx Technologies Corp. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lotus Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
InterMune Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Insmed Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Inovio Biomedical Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Infinity Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Inflazyme Pharmaceuticals Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Inhibitex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Innovive Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Interpharm Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MannKind Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Momenta Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MultiCell Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Mylan, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Mymetics Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Modigene, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Miravant Medical Technologies -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MiddleBrook Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Migenix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Millennium Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Minrad International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Myriad Genetics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
NPS Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neose Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neuro -Hitech Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neurobiological Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neurochem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
NeoPharm Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Nektar Therapeutics -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Nabi Biopharmaceuticals -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
NanoViricides, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Nastech Pharmaceutical Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
NatureWell Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Micromet Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MicroIslet, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Matrixx Initiatives Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Maxygen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Med Gen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Medarex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Marshall Edwards Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Mannatech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MGI Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MacroChem Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Manhattan Pharmaceuticals Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
ISTA Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MediciNova Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Medicis Pharmaceutical Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Merck & Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Metabasis Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Metabolic Pharmaceuticals Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
MethylGene Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Mentor Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Memory Pharmaceuticals Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Medicure Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Medivation Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Meldex International Plc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Lpath Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
ICAgen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Diamyd Medical AB -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Derma Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Discovery Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dnaprint Genomics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dov Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Depomed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dendreon Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
DOR BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
DRAXIS Health Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
DURECT Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
DUSA Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dr Reddys Laboratories Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dragon Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Eli Lilly & Co -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Elan Corp Plc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Elite Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Emergent BioSolutions Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Emisphere Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Eisai Co Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Echo Therapeutics, Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Duska Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dyax Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Dynavax Technologies Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
EPIX Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
DENTSPLY International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cytos Biotechnology AG -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Corcept Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Compugen Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cortex Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cougar Biotechnology, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Critical Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
CombinatoRx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Columbia Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cleveland Biolabs Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Clinuvel Pharmaceuticals Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cobalis Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
CollaGenex Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Crucell N V -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cubist Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
CytRx Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
CytoDyn Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cytogenix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cytokinetics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cypress Bioscience Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cyplasin Biomedical Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
CuraGen Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Curis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cyanotech Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Cyclacel Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Encysive Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Endo Pharmaceuticals Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GeoVax Labs Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GeoPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Geron Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Gilead Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GlaxoSmithKline plc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genzyme Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Gentium S.p.A -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genentech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Generex Biotechnology Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genitope Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genta Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
H.Lundbeck AS -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Halozyme Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hospira Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hologic Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Human Genome Sciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neurocrine Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
IDM Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hollis -Eden Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hi -Tech Pharmacal Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hana Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Helix BioMedix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hemispherx Biopharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Hemobiotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genelabs Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Genaera Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Eqitx Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Epigenomics AG -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Eugene Science Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Eurand N.V. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Exelixis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
EpiCept Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Enzon Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Endovasc Inc (NV) -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Enhance Biotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
EntreMed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Enzo Biochem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Flamel Technologies SA ADS -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Forbes Medi -Tech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GammaCan International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Gedeon Richter Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GelStat Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GenVec Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GW Pharmaceuticals PLC -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GTX INC -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Forest Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Forticell Bioscience, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GPC Biotech AG -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
GTC Biotherapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
IMCOR Pharmaceutical Co. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Neurologix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
SuperGen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Sunesis Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Swiss Medica Inc -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Sygnis Pharma AG -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Symbollon Pharmaceuticals Inc CL A -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Sucampo Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
Stryker Corp -Therapeutic Competitors
|
February 2008 |
£175 |
34.5 % |
|
|
